PT - JOURNAL ARTICLE AU - Urcuyo, Javier C. AU - Curtin, Lee AU - Langworthy, Jazlynn M. AU - De Leon, Gustavo AU - Anderies, Barrett AU - Singleton, Kyle W. AU - Hawkins-Daarud, Andrea AU - Jackson, Pamela R. AU - Bond, Kamila M. AU - Ranjbar, Sara AU - Lassiter-Morris, Yvette AU - Clark-Swanson, Kamala R. AU - Paulson, Lisa E. AU - Sereduk, Chris AU - Mrugala, Maciej M. AU - Porter, Alyx B. AU - Baxter, Leslie AU - Salomao, Marcela AU - Donev, Kliment AU - Hudson, Miles AU - Meyer, Jenna AU - Zeeshan, Qazi AU - Sattur, Mithun AU - Patra, Devi P. AU - Jones, Breck A. AU - Rahme, Rudy J. AU - Neal, Matthew T. AU - Patel, Naresh AU - Kouloumberis, Pelagia AU - Turkmani, Ali H. AU - Lyons, Mark AU - Krishna, Chandan AU - Zimmerman, Richard S. AU - Bendok, Bernard R. AU - Tran, Nhan L. AU - Hu, Leland S. AU - Swanson, Kristin R. TI - Image-localized Biopsy Mapping of Brain Tumor Heterogeneity: A Single-Center Study Protocol AID - 10.1101/2022.11.14.22282304 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.14.22282304 4099 - http://medrxiv.org/content/early/2022/11/17/2022.11.14.22282304.short 4100 - http://medrxiv.org/content/early/2022/11/17/2022.11.14.22282304.full AB - Brain cancers pose a novel set of difficulties due to the limited accessibility of human brain tumor tissue. For this reason, clinical decision-making relies heavily on MR imaging interpretation, yet the mapping between MRI features and underlying biology remains ambiguous. Standard tissue sampling fails to capture the full heterogeneity of the disease. Biopsies are required to obtain a pathological diagnosis and are predominantly taken from the tumor core, which often has different traits to the surrounding invasive tumor that typically leads to recurrent disease. One approach to solving this issue is to characterize the spatial heterogeneity of molecular, genetic, and cellular features of glioma through the intraoperative collection of multiple image-localized biopsy samples paired with multi-parametric MRIs. We have adopted this approach and are currently actively enrolling patients for our ‘Image-Based Mapping of Brain Tumors’ study. Patients are eligible for this research study (IRB #16-002424) if they are 18 years or older and undergoing surgical intervention for a brain lesion. Once identified, candidate patients receive dynamic susceptibility contrast (DSC) perfusion MRI and diffusion tensor imaging (DTI), in addition to standard sequences (T1, T1Gd, T2, T2-FLAIR) at their presurgical scan. During surgery, sample locations are tracked using neuronavigation and genetic aberrations are later quantified through whole-exome and RNA sequencing. The collected specimens from this NCI-funded research study will be primarily used to generate regional maps of the spatial distribution of tumor cell density and/or treatment-related key genetic marker status across tumors, within clinically feasible time frames, to identify biopsy and/or treatment targets based on insight from the entire tumor makeup regional histologic and genetic makeup. This type of methodology, when delivered within clinically feasible time frames, has the potential to further inform medical decision-making by improving surgical intervention, radiation, and targeted drug therapy for patients with glioma. From October 1, 2017 to October 31, 2022, this study has enrolled 186 patients with 197 surgeries, of which 163 resulted in the successful collection of image-guided biopsy samples. A total of 995 biopsies have been collected of which 962 are image localized, with a mean of 5.90 image-localized samples per surgery.Competing Interest StatementKRS and LSH are co-founders of Precision Oncology Insights Inc; Imaging Biometrics (medical advisory board: LSH); the remaining authors have no relevant conflicts of interest to disclose.Funding StatementThe authors gratefully acknowledge the funding that made this research possible from the NIH (R01NS060752, R01CA164371, U54CA143970, U54CA193489, U01CA220378, U54CA210180, U01CA250481), the James S. McDonnell Foundation, and the Ben and Catherine Ivy Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mayo Clinic gave ethical approval for this work. IRB# 16-002424I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors